Evidence map›Paper›PMID 41766111›Full record

ReviewCancer biology & medicine2026

First-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients.

Chuanhua Zhao, Sisi Ye, Meng Chen, Jing Qian, Jianming Xu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chuanhua ZhaoThe Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China.
Sisi YeThe Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China.
Meng ChenValue & Implementation, MSD China, Shanghai 200030, China.
Jing QianValue & Implementation, MSD China, Shanghai 200030, China.
Jianming XuThe Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China.ORCID 0000-0003-4467-6021

Funding

Non-communicable Chronic Diseases-National Science and Technology Major Project 2024ZD0520600
6 · The paper itself

Abstract

Emerging evidence suggests that the efficacy of immunotherapy in patients with advanced HER2-negative gastric cancer differs between Asian and non-Asian populations. This review examines potential factors contributing to these disparities, including differences in demographic and clinicopathologic characteristics, somatic mutations, molecular subtypes, tumor immunity,

Indexed as

Asian PeopleErb-b2 Receptor Tyrosine KinasesImmunotherapyStomach NeoplasmsHelicobacter InfectionsHumansTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesAsiagastric cancerHER2-negativeimmunotherapy

Identifiers

PMID41766111
PMCPMC12980032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.